NCT04608409CompletedPhase 1
Dose Escalation of Lapatinib With Paclitaxel in Ovarian Cancer
A Phase I Dose-Escalation Study on the Safety of Lapatinib With Dose-Dense Paclitaxel in Patients With Platinum-Resistant Ovarian Cancer
Source: ClinicalTrials.gov · Last updated 29 Jun 2025
Brief summary (registry, in English)
This trial will be a phase I dose-escalation study of lapatinib and paclitaxel for platinum-resistant ovarian cancer, which will establish the phase II dose for subsequent efficacy trials.
- Status (registry)
- Completed
- Phase (registry)
- Phase 1
- Study type
- Interventional
- Enrollment
- 16 (actual)
- First submitted
- 22 Oct 2020
- Start date
- 17 Mar 2021
- Primary completion date
- 17 May 2024
- Lead sponsor
- Frederick R. Ueland, M.D.
- Diseases
- Ovarian cancer
- NCT number
- NCT04608409
What you commit to
- Study type: Interventional · Phase 1
- Participants enrolled: 16
- From 17 Mar 2021 to the primary completion date, 17 May 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- receiving medications that inhibit or induce CYP3A4
- receiving any other anti-cancer investigational agents
Other illness
- hypersensitivity to lapatinib or paclitaxel
- uncontrolled intercurrent illness
- malabsorption syndrome
- congestive heart failure
Other
- baseline neuropathy greater than Grade 1
Who the study is looking for
- histologically or cytologically confirmed ovarian cancer who recur within 12 months of platinum-based chemotherapy
- ECOG performance status less than or equal to 2
- Adequate organ and marrow function at baseline
- ability to sign a written informed consent document
Age in the registry: 18 years to 100 years · Sex: Female · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Markey Cancer Center Coordinator of this site? Confirm its status | Lexington | United States | Unknown status |
Related publications
- A Phase 1 Dose Escalation of Lapatinib and Paclitaxel in Recurrent Ovarian Cancer.Cancers (Basel) · 2026 · PMID 41749879
This page is information, not medical advice. Discuss any trial with your doctor.